Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam phenotyping to predict cabazitaxel clearance
NL-OMON37899Recruiting
- Sponsor
- Meander Medical Center
- Start
- Jan 2013
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of midazolam and cabazitaxel in prostate cancer (PCa), sponsored by Meander Medical Center. Primary endpoint: Pharmacokinetics of midazolam and cabazitaxel. Started Jan 2013; status: recruiting.
02
Drugs
midazolamcabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON37899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37899.